옵션 체인은 다양한 행사가격과 만기일에 대한 Bio-Rad Laboratories의 주식 옵션 주요 데이터를 보여줍니다. 트레이더들은 이 정보를 사용하여 잠재적 거래를 분석하고 Bio-Rad Laboratories에 대한 시장 심리를 평가합니다..

Bio-Rad Laboratories (NYSE:BIO) 주식, 옵션 체인

Bio-Rad Laboratories

Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (56% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (44% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (42% of 2023 sales), Europe (31%), Asia (31%), and other (6%). Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.

Equities

News

Markets

Media

Trading Ideas

BBWI

BLDR

EPAM

FSLR

INTC

LULU

NVDA

SMCI

인플레이션 압력 완화에 따른 연방준비제도(연준)의 금리 인하 기대감, 기업 실적 호조, 인공지능(AI) 기술 잠재력에 대한 낙관론 덕분에 올해 주식시장은 견고한 상승세를 보였다.

S&amp;P 500는 사상 최고치에 밑돌며 상반기 마감: 하반기 성과를 좌우할 수 있는 5 종목

Bio-Rad Laboratories, Inc. Class A Common Stock

Bio-Rad Laboratories Inc

Bio-Rad Laboratories, Inc. Class B Common Stock

Bioage Labs Inc

BIOASIS TECHNOLOGIES INC by Bioasis Technologies Inc.

Bioasis Technologies Inc

Biocept Inc COM PAR $0.0001 NEW 2023

Biocept Inc

Bio Essence Corp

Blue Biofuels Inc

BIOCARTIS GROUP NV by BIOCARTIS GROUP NV

BioGaia AB

Biome Grow Inc

Biolase Inc COM PAR $.001 NEW

Biolase Inc

BIONITROGEN HLDGS CORP by BioNitrogen Holdings Corp.

BioNitrogen Holdings Corp

Bioqual Inc

Biora Therapeutics Inc

L&G PHARMA BREAKTHROUGH GO UCITS ETF

BioPassport Token

SWEDISH ORPHAN BIOVIT ORD by Swedish Orphan Biovitrum AB

Swedish Orphan Biovitrum AB

SWEDISH ORPHAN BIOVITRUM ORD

Bioceres Crop Solutions Corp. - Ordinary Shares

Bioceres Crop Solutions Corp

Biosyent Inc

General

BIOA

CORRECTION: Bioage Labs Ticker Is "BIOA"

WIIM

Bio-Rad Laboratories shares are trading higher after Citigroup maintained a Buy rating on the stock and raised its price target from $400 to $450.

Citigroup analyst Patrick Donnelly maintains Bio-Rad Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BIO#NYSE">BIO</a>) with a Buy and raises the price target from $400 to $450.

Price Target

Analyst Ratings

Citigroup Maintains Buy on Bio-Rad Laboratories, Raises Price Target to $450

RBC Capital analyst Conor McNamara maintains Bio-Rad Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BIO#NYSE">BIO</a>) with a Outperform and raises the price target from $446 to $469.

RBC Capital Maintains Outperform on Bio-Rad Laboratories, Raises Price Target to $469

Bio-Rad Laboratories shares are trading higher after the company reported better-than-expected Q3 financial results.

Bio-Rad Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BIO#NYSE">BIO</a>) reported quarterly earnings of $2.01 per share which beat the analyst consensus estimate of $1.16 by 73.28 percent. The company reported quarterly sales of $649.729 million which beat the analyst consensus estimate of $628.174 million by 3.43 percent. This is a 2.79 percent increase over sales of $632.124 million the same period last year.

Earnings

Earnings Beats

Bio-Rad Laboratories Q3 2024 Adj. EPS $2.01 Beats $1.16 Estimate, Sales $649.729M Beat $628.174M Estimate

Throughout the last three months, 5 analysts have evaluated Bio-Rad Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BIO#NYSE">BIO</a>), offering a diverse set of opinions from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $378.4, a high estimate of $401.00, and a low estimate of $340.00. This upward trend is evident, with the current average reflecting a 4.17% increase from the previous average price target of $363.25.
<img src="https://www.benzinga.com/files/images/story/2024/1727791258_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
The standing of Bio-Rad Laboratories among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patrick Donnelly</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$400.00</td>
<td>$350.00</td>
</tr>
<tr>
<td>Brandon Couillard</td>
<td>Wells Fargo</td>
<td>Announces</td>
<td>Equal-Weight</td>
<td>$340.00</td>
<td>-</td>
</tr>
<tr>
<td>Conor McNamara</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$401.00</td>
<td>$401.00</td>
</tr>
<tr>
<td>Conor McNamara</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$401.00</td>
<td>$402.00</td>
</tr>
<tr>
<td>Patrick Donnelly</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$350.00</td>
<td>$300.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Bio-Rad Laboratories. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Bio-Rad Laboratories compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Bio-Rad Laboratories's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Bio-Rad Laboratories's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/BIO/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Bio-Rad Laboratories analyst ratings.</a>
<h2>Unveiling the Story Behind Bio-Rad Laboratories</h2>
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (56% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (44% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (42% of 2023 sales), Europe (31%), Asia (31%), and other (6%). Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.
<h3>Financial Milestones: Bio-Rad Laboratories's Journey</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Bio-Rad Laboratories's revenue growth over a period of 3 months has faced challenges. As of 30 June, 2024, the company experienced a revenue decline of approximately -6.26%. This indicates a decrease in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Bio-Rad Laboratories's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of -339.16%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Bio-Rad Laboratories's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -27.36%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -19.42%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: With a below-average debt-to-equity ratio of 0.21, Bio-Rad Laboratories adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>Analyst Ratings: Simplified</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Expert Ratings For Bio-Rad Laboratories

Citigroup analyst Patrick Donnelly upgrades Bio-Rad Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BIO#NYSE">BIO</a>) from Neutral to Buy and raises the price target from $350 to $400.

Upgrades

Citigroup Upgrades Bio-Rad Laboratories to Buy, Raises Price Target to $400

The S&amp;P 500 is a widely recognized benchmark for the US stock market, and it has undergone reshuffling due to the quarterly rebalancing process. This shake-up, driven by shifts in company performance and market capitalization, provides a unique lens into the evolving dynamics of the business world. The inclusion of several companies reflects a changing market terrain. Conversely, the departure of others underscores the challenges and transitions faced within their respective industries.&nbsp;
<h2>A Glimpse Into the S&amp;P 500</h2>
The S&amp;P 500 index is a market capitalization-weighted index, meaning that companies with a larger market cap have a more significant influence on the index&#39;s performance. This index is a barometer of the US stock market, offering investors a diversified representation of the largest publicly traded companies. Each quarter, S&amp;P Dow Jones Indices carefully reviews and adjusts the S&amp;P 500 to reflect changes in company performance and market capitalization. The most recent rebalancing saw three companies join the index and three companies leave the index.&nbsp;
<h3>Palantir: Data Analytics Powerhouse Enters the Big League</h3>
Palantir Technologies (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/pltr#NYSE">PLTR</a>) is a leading data analytics and software company that has joined the S&amp;P 500 index, signifying its significant growth and market influence. Palantir specializes in real-time data analysis and prediction services, leveraging advanced artificial intelligence (AI) technologies to unlock insights for diverse clients, including government agencies, financial institutions, and healthcare organizations.
Palantir&#39;s stock has experienced a remarkable 160% surge over the past 12 months and over a 100% increase year-to-date (YTD), reflecting the increasing demand for data-driven solutions. The company&#39;s expertise has attracted significant contracts, including a $480 million deal with the US Department of Defense. This commitment from the defense sector, combined with a growing commercial presence, underscores Palantir&#39;s adaptability across various industries.
Palantir&#39;s inclusion in the S&amp;P 500 is a significant milestone leading to increased investor awareness, access to a broader range of investors, and inclusion in various index funds. This inclusion solidifies Palantir&#39;s position as a significant player in the expanding data analytics sector.
<h3>Dell Technologies: A Technology Giant Reinforces Its Position</h3>
Dell Technologies (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/dell#NYSE">DELL</a>) is a long-standing leader in the technology industry, and it has further cemented its standing by joining the ranks of the S&amp;P 500. The company&#39;s diverse portfolio, encompassing computer hardware, software, and comprehensive IT solutions, positions it as a major player in the ever-evolving technology sector.
Dell&#39;s enduring success stems from its ability to adapt to changing market demands and innovate across its key segments: PCs, servers, storage, and software.
The company&#39;s recent performance reflects this adaptability, with a healthy stock price increase of 67% over the past 12 months and over 50% YTD. This growth trajectory is driven by Dell&#39;s commitment to expanding its product offerings, particularly in cloud computing and cybersecurity, which are crucial for businesses navigating an increasingly complex digital environment.
Dell&#39;s inclusion in the S&amp;P 500 signifies its continued relevance in the technology industry and signals a strong potential for further growth. As the company leverages its comprehensive solutions and embraces emerging technological trends, investors will watch closely to see how Dell continues navigating the changes happening in the tech sector.&nbsp;
<h3>Erie Indemnity: A Steady Hand in a Volatile Market</h3>
While Palantir and Dell represent the cutting edge of tech innovation, Erie Indemnity (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/erie#NASDAQ">ERIE</a>) offers a different perspective on the S&amp;P 500. This property and casualty insurance company is known for its focus on specific market niches and for providing a steady hand in a volatile market.
Erie Indemnity stands out for its deep expertise in the auto insurance market, a segment where it has built a solid reputation for its customer-centric approach and competitive pricing. This strategic focus has been a key driver of its success, allowing it to navigate industry fluctuations and build a loyal customer base.
Despite the challenges faced by the insurance industry, Erie Indemnity has maintained consistent growth. Its stock has gained around 80% over the past 12 months and 55% YTD, showcasing a track record of steady growth. This performance reflects the company&#39;s ability to manage risk effectively and cater to the evolving needs of its target audience. As the auto insurance market continues to evolve, Erie Indemnity&#39;s focus on niche expertise and its commitment to financial health make it an attractive investment option for those seeking consistent, stable returns.
<h2>Departing Companies: A Look at Industry Shifts and Market Performance</h2>
The quarterly rebalancing of the S&amp;P 500 often sees companies move to smaller indices, reflecting changes in market dynamics and adjustments in their respective industries.&nbsp;
<h3>American Airlines: Navigating Turbulent Skies</h3>
American Airlines (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/aal#NASDAQ">AAL</a>) has faced significant headwinds in recent months. The company&#39;s stock price has declined by 15% over the past 12 months and 20% YTD, reflecting the challenging operating environment for airlines.
Factors such as rising fuel costs, increased competition, and the ongoing uncertainties in the travel sector have contributed to these declines.
American Airlines&#39; transition to the S&amp;P MidCap 400 reflects these challenges and signals the company&#39;s current market position within the broader airline industry.
<h3>Etsy: A Handcrafted Marketplace With Growing Competition</h3>
Etsy (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/etsy#NASDAQ">ETSY</a>) is an online marketplace for handmade and vintage goods that has also experienced stock price declines, falling by 16% over the past 12 months and 34% YTD.
This decline can be attributed to several factors, including growing competition from other online marketplaces, the increasing popularity of mass-produced goods, and evolving consumer preferences.
Etsy&#39;s shift to the S&amp;P SmallCap 600 index reflects its current position within the increasingly competitive e-commerce sector.
<h3>Bio-Rad Laboratories: Changing Trends in Life Sciences</h3>
Bio-Rad Laboratories (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/bio#NYSE">BIO</a>) is a leader in life sciences research and diagnostics, and the company has experienced a stock price decline of nearly 15% in the past three months and 6% over the past year.
These fluctuations are linked to broader life science industry trends, including regulatory changes, R&amp;D investment levels, and the evolving terrain of scientific research.
Bio-Rad&#39;s move to the S&amp;P MidCap 400 index reflects these market dynamics and signals the company&#39;s current position within the life sciences sector.
<h2>S&amp;P 500 Rebalancing: A Glimpse Into Market Dynamics</h2>
The recent S&amp;P 500 rebalancing gives investors a snapshot of the evolving market terrain. The inclusion of data analytics leader Palantir Technologies and tech giant Dell Technologies signals the growing significance of these sectors. Meanwhile, the departure of companies like American Airlines reflects certain industries&#39; challenges. Investors can gain valuable insights into potential growth areas and industry trends by keeping an eye on the companies entering and leaving the index.
The article &quot;<a href="https://www.marketbeat.com/originals/s-and-p-500-shake-up-new-entrants-driving-market-momentum/">S&amp;P 500 Shake-Up: New Entrants Driving Market Momentum</a>&quot; first appeared on MarketBeat.

Large Cap

Mid Cap

Offerings

Contracts

Travel

Tech

Insurance

DELL

ERIE

ETSY

PLTR

S&P 500 Shake-Up: New Entrants Driving Market Momentum

Designed to provide broad exposure to the Healthcare - Broad segment of the equity market, the Invesco S&amp;P 500 Equal Weight Health Care ETF (ARCA:RSPH) is a passively managed exchange traded fund launched on 11/01/2006.
Passively managed ETFs are becoming increasingly popular with institutional as well as retail investors due to their low cost, transparency, flexibility and tax efficiency. They are excellent vehicles for long term investors.
Sector ETFs are also funds of convenience, offering many ways to gain low risk and diversified exposure to a broad group of companies in particular sectors. Healthcare - Broad is one of the 16 broad Zacks sectors within the Zacks Industry classification. It is currently ranked 4, placing it in top 25%.
<h2>Index Details</h2>
The fund is sponsored by Invesco. It has amassed assets over $953.37 million, making it one of the larger ETFs attempting to match the performance of the Healthcare - Broad segment of the equity market. RSPH seeks to match the performance of the S&amp;P 500 EQUAL WEIGHT HEALTH CARE INDEX before fees and expenses.
The S&amp;P 500 Equal Weight Health Care Index equally weights stocks in the health care sector of the S&amp;P 500 Index.
<h2>Costs</h2>
Expense ratios are an important factor in the return of an ETF and in the long term, cheaper funds can significantly outperform their more expensive counterparts, other things remaining the same.
Annual operating expenses for this ETF are 0.40%, making it one of the cheaper products in the space.
It has a 12-month trailing dividend yield of 0.61%.
<h2>Sector Exposure and Top Holdings</h2>
ETFs offer a diversified exposure and thus minimize single stock risk but it is still important to delve into a fund&#39;s holdings before investing. Most ETFs are very transparent products and many disclose their holdings on a daily basis.
This ETF has heaviest allocation in the Healthcare sector--about 100% of the portfolio.
Looking at individual holdings, Bio-Rad Laboratories Inc (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/bio#NYSE">BIO</a>) accounts for about 1.82% of total assets, followed by Bristol-Myers Squibb Co (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/bmy#NYSE">BMY</a>) and Gilead Sciences Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gild#NASDAQ">GILD</a>).
The top 10 holdings account for about 17.87% of total assets under management.
<h2>Performance and Risk</h2>
So far this year, RSPH has gained about 7.38%, and is up about 12.94% in the last one year (as of 09/12/2024). During this past 52-week period, the fund has traded between $25.30 and $32.39.
The ETF has a beta of 0.84 and standard deviation of 16.29% for the trailing three-year period. With about 65 holdings, it effectively diversifies company-specific risk.
<h2>Alternatives</h2>
Invesco S&amp;P 500 Equal Weight Health Care ETF carries a Zacks ETF Rank of 3 (Hold), which is based on expected asset class return, expense ratio, and momentum, among other factors. Thus, RSPH is a sufficient option for those seeking exposure to the Health Care ETFs area of the market. Investors might also want to consider some other ETF options in the space.
Vanguard Health Care ETF (ARCA:VHT) tracks MSCI US Investable Market Health Care 25/50 Index and the Health Care Select Sector SPDR ETF (ARCA:XLV) tracks Health Care Select Sector Index. Vanguard Health Care ETF has $18.69 billion in assets, Health Care Select Sector SPDR ETF has $41.93 billion. VHT has an expense ratio of 0.10% and XLV charges 0.09%.
<a href="https://www.zacks.com/stock/news/2335012/should-you-invest-in-the-invesco-s-p-500-equal-weight-health-care-etf-rsph?cid=CS-BENZ-FT-sector_etf-2335012">To read this article on Zacks.com click here.</a>

Biotech

Sector ETFs

Dividends

Health Care

ETFs

GILD

RSPH

Should You Invest in the Invesco S&P 500 Equal Weight Health Care ETF?

Palantir Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NYSE">PLTR</a>) is gearing up for a significant milestone: its inclusion in the S&amp;P 500 index, <a href="https://www.benzinga.com/markets/equities/24/09/40769921/palantir-stock-soars-in-monday-premarket-whats-driving-the-surge">effective Sept. 23</a>.
<h2 class="wp-block-heading">S&amp;P 500 Inclusion Boosts Palantir's Stock</h2>
This move will see Palantir replace American Airlines Group Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAL#NASDAQ">AAL</a>), Etsy Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ETSY#NASDAQ">ETSY</a>) and Bio-Rad Laboratories Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIO#NASDAQ">BIO</a>). 
Historically, inclusion in this prestigious index tends to drive up stock prices due to increased buying from index funds and ETFs. 
Palantir shares have already seen a notable uptick, jumping over 10% on Monday.
<h2 class="wp-block-heading">New Enterprise Deal Fuels Pre-Market Surge</h2>
This rise is also fueled by the company's latest enterprise agreement with BP PLC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BP#NYSE">BP</a>), aimed at extending their strategic relationship. The deal will introduce new AI capabilities with Palantir's AIP software, further boosting investor confidence.
The collaboration highlights Palantir's growing influence in the AI space and its expanding commercial footprint.
Read Also: <a href="https://www.benzinga.com/markets/equities/24/09/40769921/palantir-stock-soars-in-monday-premarket-whats-driving-the-surge">Palantir Stock Soars In Monday Premarket: What&#8217;s Driving The Surge?</a>
<h2 class="wp-block-heading">Palantir Stock: Bulls Vs. Bears</h2>
Technically, Palantir's stock is showing a bullish picture. 
<figure class="wp-block-image size-full"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent090924&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="632" height="463" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/09091705/Screenshot-2024-09-09-at-6.46.45-PM.png" alt="" class="wp-image-537465" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/09091705/Screenshot-2024-09-09-at-6.46.45-PM.png 632w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/09091705/Screenshot-2024-09-09-at-6.46.45-PM-300x220.png 300w" sizes="(max-width: 632px) 100vw, 632px" /></a></figure>
<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent090924&amp;t=be2bearmibe3na1">Chart created using Benzinga Pro</a>
Currently trading at $32.94, it's above its 50-day SMA of $28.83 and 200-day SMA of $23.14, signaling long-term bullish momentum. The stock&#8217;s price is currently above both the eight-day and 20-day SMAs, at $30.92 and $31.21, respectively, indicating short-term buying pressure. This suggests a positive overall trend and points to a potential bullish trajectory moving forward.
Palantir's upcoming S&amp;P 500 inclusion and new enterprise deal with BP are significant drivers of its recent stock performance. 
Investors should watch for how these factors interact with the technical indicators as the company prepares for its S&amp;P debut and continues to expand its AI capabilities.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/09/40766713/palantirs-s-p-500-inclusion-another-validation-moment-as-it-embarks-on-new-era-of-e">Palantir&#8217;s S&amp;P 500 Inclusion &#8216;Another Validation Moment&#8217; As It Embarks On New Era Of Enterprise Growth And Profitability, Says Bullish Analyst</a></li>
</ul>
Photo: Shutterstock

Technicals

Palantir Stock Soars After S&P 500 Inclusion, AI Deal With BP Fuels Additional Gains – What's Next?

<a href="https://www.spglobal.com/spdji/en/documents/indexnews/announcements/20240906-1474143/1474143_septembershuffle546.pdf">https://www.spglobal.com/spdji/en/documents/indexnews/announcements/20240906-1474143/1474143_septembershuffle546.pdf</a>
Palantir Technologies, Dell Technologies, and Erie Indemnity Set to Join S&amp;P 500; Others to Join S&amp;P MidCap 400 and S&amp;P SmallCap 600
&nbsp;
NEW YORK, September 6, 2024: S&amp;P Dow Jones Indices (&quot;S&amp;P DJI&quot;) will make the following changes to the S&amp;P 500, S&amp;P MidCap 400, and S&amp;P SmallCap 600 indices effective prior to the open of trading on Monday, September 23, to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market capitalization range. All companies being added to the S&amp;P 500 are more representative of the large-cap market space, all companies being added to the S&amp;P MidCap 400 are more representative of the mid-cap market space, and all companies being added to the S&amp;P SmallCap 600 are more representative of the small-cap market space. The companies being removed from the S&amp;P SmallCap 600 are no longer representative of the small-cap market space. 
&nbsp;
Palantir Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NYSE">PLTR</a>), Dell Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DELL#NYSE">DELL</a>), and S&amp;P MidCap 400 constituent Erie Indemnity Co. (NASD:ERIE) will replace American Airlines Group Inc. (NASD:AAL), Etsy Inc. (NASD:ETSY) and Bio-Rad Laboratories Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BIO#NYSE">BIO</a>) in the S&amp;P 500, respectively. American Airline Group will replace TEGNA Inc.&nbsp;in the S&amp;P MidCap 400, and TEGNA will replace Designer Brands Inc. in the S&amp;P SmallCap 600. Etsy will replace Haverty Furniture Companies Inc.&nbsp;in the S&amp;P SmallCap 600. Bio-Rad Laboratories will replace Erie Indemnity in the S&amp;P MidCap 400.

Small Cap

Palantir Technologies, Dell Technologies, And S&P MidCap 400 Constituent Erie Indemnity Co. Set To Join S&P 500; Will Replace American Airlines Group, Etsy And Bio-Rad Laboratories

Wells Fargo analyst Brandon Couillard initiates coverage on Bio-Rad Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BIO#NYSE">BIO</a>) with a Equal-Weight rating and announces Price Target of $340.

Initiation

Wells Fargo Initiates Coverage On Bio-Rad Laboratories with Equal-Weight Rating, Announces Price Target of $340

Bio-Rad Laboratories, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BIO#NYSE">BIO</a>), a global leader in life science research and clinical diagnostics products, today announced that Jon DiVincenzo will join the company as President and Chief Operating Officer, effective September 9, 2024, replacing Andy Last, who is retiring.
Mr. DiVincenzo joins Bio-Rad from Labcorp Holdings Inc., a global provider of comprehensive laboratory services, where he held various global operational and commercial leadership roles across the company's several business units. Most recently, he served as Executive Vice President and President, Central Laboratories and International. Prior to LabCorp, Mr. DiVincenzo was President of the Environmental Health Division at PerkinElmer, a global company focused on diagnostics, life science research, food quality, environmental health and industrial testing. He also served as Chief Executive Officer of Enzymatics, a privately held molecular biology reagents company. Prior to that, Mr. DiVincenzo held roles of increasing responsibility in the Biosciences and Lab Water businesses of EMD Millipore, a subsidiary of Merck KGaA. He holds a Bachelor of Science degree in mechanical engineering from Northeastern University.

Management

Bio-Rad Appoints Jon DiVincenzo As President And Chief Operating Officer, Effective September 9, 2024, Replacing Andy Last, Who Is Retiring

RBC Capital analyst Conor McNamara reiterates Bio-Rad Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BIO#NYSE">BIO</a>) with a Outperform and maintains $401 price target.

Reiteration

RBC Capital Reiterates Outperform on Bio-Rad Laboratories, Maintains $401 Price Target

Bio-Rad&#39;s (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/bio#NYSE">BIO</a>) business performance has been affected by Biopharma&#39;s softness, macroeconomic conditions in China and competitive pressure. The stock carries a Zacks Rank #4 (Sell).
Since the beginning of 2023, Bio-Rad has been witnessing softness in smaller BioPharma companies, where historically, demand for life science products has been strong. This directly correlates with the funding constraints the broader pharmaceutical industry has been experiencing. Management puts forth that BioPharma&#39;s softness has resulted in the Life Science Segment&#39;s growth at a slower pace.
In the second quarter of 2024, negative BioPharma macro trends persisted. Bio-Rad experienced reduced demand from biopharma customers for its process chromatography resins and from both biopharma and smaller biotech customers for Life Science research products, reflecting the ongoing destocking trend across the industry. Bio-Rad experienced weaker second-quarter sales in Asia as China is currently entangled in a challenging research funding environment and Japan too is facing constrained funding issues. Additionally, the Korean government&#39;s spending on life science research remained soft throughout the second quarter as part of the deficit reduction.
In recent times, Bio-Rad&#39;s margin performance has been affected by elevated raw material costs, increased logistics costs and higher employee-related expenses. In the second quarter, the company&#39;s gross margin was additionally impacted by an unfavorable product mix, with a higher-than-anticipated percentage of instrument sales versus reagents, as well as lower-than-projected revenues in the Life Science Group.
<div class="chart_embed">
<h3>Bio-Rad Laboratories, Inc. Price</h3>
<img alt="Bio-Rad Laboratories, Inc. Price" src="https://staticx-tuner.zacks.com/images/charts/36/1723467995.png" style="height:251px; width:545px" title="" />
Bio-Rad Laboratories, Inc. price | Bio-Rad Laboratories, Inc. Quote
These macroeconomic factors, particularly the ongoing labor unrest, rising wages and raw material costs, along with ongoing geopolitical unrest, are resulting in a significant escalation in the company&#39;s operating expenses. Bio-Rad posted a 27.8% year-over-year decline in operating profit in the second quarter. Based on all these factors, Bio-Rad lowered its adjusted operating margin projection for 2024 to 12-13% (down from the earlier guidance of 13.5-14%). For 2024, our model projects a 10.6% decline in the company&#39;s GAAP operating profit on a 3.7% rise in expenses.&nbsp;
</div>
Meanwhile, Bio-Rad operates in a highly competitive environment dominated by firms varying from large multinational corporations with significant resources to start-ups. Also, the competitive and regulatory conditions in the markets where the company operates limit Bio-Rad&#39;s ability to switch to strategies like price increases and other drivers of cost increases. Further, the extension of the public tender commitments to multiple years by the government, resulting in a reduced number of annual tenders, has led to aggressive tender pricing by Bio-Rad&#39;s competitors. Thus, Bio-Rad faces pricing pressure resulting from increased competition, which makes it difficult for the company to manage its operational, financial and business conditions efficiently.
On a positive note, Bio-Rad is consistently developing its foothold in the rapidly growing digital PCR space to address additional opportunities in the PCR market. The pipeline of Bio-Rad&#39;s QX600 Droplet Digital PCR (ddPCR) platform is currently robust and growing. Backed by the tremendous customer response, the company continues to ramp up production capacity to accommodate the ongoing demand.
In the second quarter, despite the Droplet Digital PCR franchise being soft, ddPCR reagents and consumables grew low in single digits. The newly launched ddPCR assay is successfully gaining share in the oncology and cell and gene therapy markets. Considering all these factors, the company is optimistic about ddPCR&#39;s growth in the coming quarters.
Sales of the clinical diagnostics group in the second quarter increased 2.1% on a reported basis and 3.2% on a currency-neutral basis. Growth of the clinical diagnostics group was primarily backed by increased demand for quality controls and blood typing products on a geographic basis. Currency-neutral year-over-year revenues in the diagnostics group posted balanced growth across all regions of the company. The company continues to invest in supporting the growth of this segment while building a position in new molecular diagnostics segments.
<h3>Key Picks</h3>
Some better-ranked stocks in the broader medical space are&nbsp;Universal Health Service&nbsp;(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/unh#NYSE">UNH</a>),&nbsp;Quest Diagnostics&nbsp;(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/dgx#NYSE">DGX</a>) and&nbsp;ABM Industries&nbsp;(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/abm#NYSE">ABM</a>). While Universal Health Service sports a Zacks Rank #1 (Strong Buy), Quest Diagnostics and ABM Industries carry a Zacks Rank #2 (Buy) each.
Universal Health Service has an estimated long-term growth rate of 19%. UHS&#39; earnings surpassed estimates in each of the trailing four quarters, with the average being 14.58%.
Universal Health Service has gained 41.1% compared with the&nbsp;industry&#39;s&nbsp;34.8% rise so far this year.
Quest Diagnostics has an estimated long-term growth rate of 6.20%. DGX&#39;s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 3.31%.
Quest Diagnostics shares have gained 3.7% so far this year compared with the&nbsp;industry&#39;s&nbsp;10.2% rise.
ABM Industries&#39; earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 7.34%.
ABM&#39;s shares have risen 24.1% so far this year compared with the&nbsp;industry&#39;s&nbsp;11.9% growth.
<a href="https://www.zacks.com/stock/news/2320781/bio-rad-bio-faces-low-biopharma-demand-competitive-pressure?cid=CS-BENZ-FT-analyst_blog|zer_report_update-2320781">To read this article on Zacks.com click here.</a>

Guidance

Bio-Rad Faces Low BioPharma Demand, Competitive Pressure

RBC Capital analyst Conor McNamara maintains Bio-Rad Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BIO#NYSE">BIO</a>) with a Outperform and lowers the price target from $402 to $401.

RBC Capital Maintains Outperform on Bio-Rad Laboratories, Lowers Price Target to $401

Citigroup analyst Patrick Donnelly maintains Bio-Rad Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BIO#NYSE">BIO</a>) with a Neutral and raises the price target from $300 to $350.

Citigroup Maintains Neutral on Bio-Rad Laboratories, Raises Price Target to $350

Bio-Rad Expects FY24 Non-GAAP Revenue To Decline 2.5-4% vs Prior Estimate Of Declining 1-2.5%

Bio-Rad Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BIO#NYSE">BIO</a>) reported quarterly earnings of $3.11 per share which beat the analyst consensus estimate of $2.01 by 54.73 percent. The company reported quarterly sales of $638.500 million which missed the analyst consensus estimate of $645.789 million by 1.13 percent. This is a 6.25 percent decrease over sales of $681.100 million the same period last year.

Earnings Misses

Bio-Rad Laboratories Q2 2024 Adj. EPS $3.11 Beats $2.01 Estimate, Sales $638.5M Miss $645.789M Estimate

Longleaf Partners Fund Q3 2024 Commentary

ESG 'transition' funds are an emerging trend – Here the most overweight stocks by ESG funds

RBC Capital analyst Conor McNamara maintained a Buy rating on Bio-Rad Laboratories (BIO – Research Report) on October 23 and set a price target of ...

Bio-Rad Laboratories (BIO) Gets a Buy from RBC Capital

Bio-Rad Labs Q3 2024 Earnings Preview

Here are the major earnings after the close today

Bio-Rad Laboratories, Inc. (BIO) Q3 2024 Earnings Call Transcript

Bio-Rad Laboratories ( ($BIO) ) has realeased its Q3 earnings. Here is a breakdown of the information Bio-Rad Laboratories presented to its investo...

Bio-Rad Laboratories Reports Q3 2024 Earnings Growth

Bio-Rad Labs misses Q3 estimates for profit, revenue

In a report released yesterday, Brandon Couillard from Wells Fargo maintained a Hold rating on Bio-Rad Laboratories (BIO – Research Report), with a...

Wells Fargo Remains a Hold on Bio-Rad Laboratories (BIO)

Ariel Investments Focus Fund Q3 2024 Commentary

ACGL

ACHC

AEIS

ALGT

ALTR

AMRN

AMSC

AMWL

APTV

ATEC

AXAHY

BALL

BECN

BKNG

CHTR

ENPH

ESGD

ESGG

ESGU

ESGV

GNRC

HOOD

HTGC

HUBG

IDXX

IMAX

INVH

IRTC

JAKK

KLAC

LMND

LPLA

MATX

MGRB

MGRD

MGRE

MSFT

ORCL

PARA

POOL

PPSI

PYPL

RIOT

ROOT

SBUX

SIMO

SNBR

SPOK

SPXC

SSNLF

STAA

STEM

TDOC

TENB

VLTO

VRSK

OncoCyte's Innovative Approach: Potential in Precision Diagnostics

Press Releases

Bio-Rad to Report Second Quarter Financial Results on Thursday, August 1, 2024

Bio-Rad Reports Second-Quarter 2024 Financial Results

Oncocyte Announces Successful GraftAssure™ Beta Launch and Q2 2024 Results

Bio-Rad Appoints Jon DiVincenzo President, Chief Operating Officer

Bio-Rad's Management to Participate in Fireside Chat During Wells Fargo's 2024 Healthcare Conference

Palantir Technologies, Dell Technologies, and Erie Indemnity Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600

Bio-Rad to Report Third Quarter 2024 Financial Results on Wednesday, October 30, 2024

Bio-Rad Reports Third-Quarter 2024 Financial Results

Bio-Rad's Management to Participate in Fireside Chat During UBS Global Healthcare Conference

Comments

Bio-Rad Laboratories

Bio-Rad Laboratories (BIO) 옵션

Bio-Rad Laboratories (NYSE:BIO) 주식, 옵션 체인

뉴스

파트너 / 기고자

벤징가 글로벌